Introduction
Nasopharyngeal carcinoma (NPC) is uncommon with approximately 87,000 new cases which accounted for 0.6% of all cancers diagnosed worldwide in 2012 (1) . The majority of cases are found in east and southeast Asia, north Africa, Middle East and the Arctic (2) . NPC is a distinctive cancer that differs from other head and neck malignancies in terms of its pathogenesis, clinical progression and management strategy (3, 4) . It is classified into three pathological subtypes: keratinising squamous cell carcinoma (SCC), nonkeratinising carcinoma (which comprises differentiated and undifferentiated types) and basaloid SCC (5) . The Epstein-Barr virus (EBV) is implicated in the development of NPC, particularly in the endemic non-keratinising subtype with specific expression of several latent genes. These include the EBV nuclear antigen (EBNA1), latent membrane proteins (LMP1, LMP2) and EBV encoded noncoding RNAs (EBERs) in contrast to the conventional risk factors associated with head and neck SCC (HNSCC) (6, 7) .
Definitive (chemo)radiotherapy is the primary treatment modality in NPC with little role for surgical intervention apart from in the salvage setting. There have been few significant breakthroughs in the management of this disease since the introduction of concurrent chemoradiation in those with advanced disease which yielded 5-year overall survival (OS) rates between 67-81% and locoregional control rates of 78-90% (3) . Efforts to improve these figures by means of induction chemotherapy or altered radiotherapy fractionation have been disappointing (8, 9) . Perhaps a more personalised and targeted approach is required to improve clinical outcomes in NPC.
Review Article
Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging Intratumoral hypoxia is an important negative prognostic factor in HNSCC (10, 11) . However, most if not all of these studies excluded patients with NPC and thus, the actual prevalence of hypoxia in the NPC population is still unclear. Intratumoral hypoxia is an important predictive factor for radiotherapy, and to a lesser extent, chemotherapy response (12) . This could be particularly pertinent in the predominantly non-surgical management of NPC. Intratumoral oxygenation is a dynamic process which is dependent on cellular extraction or utilisation of oxygen, oxygen transport capacity, vascular perfusion and interstitial pressure (13) . Conventional classification of acute hypoxia due to perfusion changes, chronic hypoxia due to increased perfusion distance in larger tumours and hypoxaemic hypoxia due to reduced oxygen transport capacity are not mutually exclusive and it is extremely difficult to clinically establish the contribution of each component to the overall tumour oxygenation status (14) . The exact partial oxygen pressure (pO 2 ) level which defines hypoxia is dependent on the tissue or tumour type but should be the critical level that impairs normal cellular function (15). This critical pO 2 level is usually between 8 to 10 mmHg in most tumour types but the pO 2 level which causes treatment resistance could be higher and again, varies with the treatment modality involved (13) . This review aims to assess the prevalence and relevance of hypoxia in NPC and to evaluate the role of non-invasive molecular hypoxia imaging in this disease.
Evidence of hypoxia in NPC
Overall, there is scant evidence in the published literature regarding the actual prevalence of hypoxia in NPC. The very limited pO 2 data that is available suggests that NPC tumours can be hypoxic but what proportion of nasopharyngeal tumours is indeed hypoxic is unclear. The data from pathological hypoxia assessment in NPC suggests that up to half of these tumours have some degree of hypoxia. However, whether these endogenous markers are true reflections of intratumoral oxygenation status is still debatable. In HNSCC, the proportion of hypoxic tumours can be as high as 58% and tumour oxygenation did not seem to differ between primary and nodal metastases (14, 16) . However, in view of the different pathogenesis and risk factors implicated in NPC, particularly the endemic form, and HNSCC which has a higher proportion of smokers and drinkers and hence, greater risk of vasculopathy, the prevalence of extreme hypoxia in NPC may be lower compared to SCC. Nonetheless, hypoxia in NPC may still be a significant problem particularly in those with bulky locoregional disease.
To date, there is no published study that examined the prevalence of intratumoral oxygenation in NPC by means of pO 2 measurement. A number of studies have evaluated the prevalence of hypoxia using polarographic needle electrode histography in head and neck cancers which included predominantly SCCs (17) (18) (19) (20) (21) (22) (23) (24) (25) . Polarographic needle electrode histography is an automated system which uses a 250-350 μm oxygen-sensitive probe which is inserted into the tumour and progresses in a stepwise pattern over a predetermined distance, enabling multiple real-time pO 2 sampling within the tumour with fine spatial resolution (14, 19) . This method is considered the gold standard in intratumoral oxygenation measurement although it has several important limitations. Firstly, repeated assessment during therapy is difficult due to its invasive nature and it is not suitable for deep seated tumours. It cannot distinguish viable tumours from necrotic tissue and thus, will require additional imaging or pathological assessment for this purpose.
Other methods of tumour hypoxia assessment are quantification of downstream endogenous genomic or proteomic markers involved in hypoxia-induced cellular signalling such as hypoxia-inducible factors (HIFs), carbonic anhydrase IX (CA-IX), glucose transporter 1 (GLUT1) and osteopontin (OPN). A noteworthy study investigated the in vitro hypoxic induction of HIF-1α, HIF-2α, CA-IX and vascular endothelial growth factor (VEGF) at the mRNA and proteomic levels in four NPC cell lines representing all NPC subtypes: keratinising SCC (HK1), undifferentiated carcinoma (C666-1) and poorly differentiated carcinoma (HONE-1, CNE-2) (26). HIF-1α expression was increased after 16 hours of hypoxia exposure in all four cell lines. Expression of CA-IX was also increased in 3 cell lines but not C666-1. However, VEGF expression was only increased after 24 hours of hypoxia exposure in C666-1, HONE1 and CNE-2 cells. HIF-2α expression was not increased in any of the cell lines following hypoxia exposure. The group also performed microarray analysis profiling hypoxic and normoxic gene expressions in HONE-1 and CNE-2 cells which showed that 4.6-7.6% of measured transcripts were regulated by hypoxia. Overall, these results suggest that the transcription and translation of hypoxic genes are probably dependent on both tumour type and duration of hypoxia exposure. OPN is a phosphoglycoprotein that is found in tumours, some normal tissues and body fluids (27) . It is implicated in tumour invasion, migration and metastasis.
Research has mostly concentrated on the role of plasma OPN as a hypoxic biomarker which is thought to be shed primarily from tumour cells (28) . However, this assumption should be reconsidered as plasma OPN may be derived from other tissues such as bones, immune and endothelial cells (27) . In fact, OPN expression was restricted to tumourinfiltrating macrophages, not tumour cells in pancreatic adenocarcinoma (29) . Whether plasma and intratumoral OPN levels can be used interchangeably as a hypoxic biomarker, if indeed it is one, could perhaps be answered by a study by Nordsmark et al. which failed to show any correlation between the blood and intratumoral OPN levels (30) . In addition, OPN secretion was found to be cell line dependent and increased by reoxygenation, rather than hypoxia exposure in an in vitro study (31) . These findings were supported by an in vivo study which found that intratumoral and plasma OPN levels were dependent on the strains of mice and tumour models, and OPN levels were increased by reoxygenation rather than prolonged hypoxia exposure (32) . Despite the uncertainty of OPN as a true hypoxic biomarker, plasma OPN has been shown to be a significant prognostic marker in HNSCC (28, 33) . Although immunohistochemistry is easy to perform in clinical practice, these endogenous markers are not purely specific to hypoxia and may be affected by other biological processes in the tumour microenvironment (34) . Pathological assessment is also not representative of what is happening at the whole tumour level due to sampling limitation. The cost of hypoxic genomic analysis prohibits its routine use in clinical practice at present although this may change in the future. Moreover, one cannot assume that hypoxia-induced gene expression or repression will lead to corresponding proteomic changes (35) , which adds another layer of complexity in applying genomic or downstream proteomic hypoxic biomarkers to direct treatment in the clinic. In view of the potential importance of hypoxia in NPC, we will review the available evidence of hypoxia as measured using polarographic needle electrode system and pathological assessment in NPC.
A German group showed that pO 2 status in primary and nodal tumours were not significantly different in 15 HNSCC patients who had simultaneous pO 2 sampling of their primary and nodal tumours (17) . The study included one patient with nasopharyngeal SCC who had nodal pO 2 sampling only. The median nodal pO 2 for this patient was 13.5 mmHg and hypoxic fraction (HF) which was defined as the percentage of pO 2 readings with values below 5.0 mmHg (HF 5.0 ) was 0%. Brizel et al. acquired pretreatment pO 2 measurements from 28 locally advanced HNSCC cases which included one patient with a nasopharyngeal primary (21) . In contrast to the previous study, the median nodal pO 2 for this patient was 3.8 mmHg and HF 5.0 was 36%. An update of the latter study (n=63) included one additional NPC primary but no individual pO 2 data were available (22) . Adam et al. measured tumour oxygenation in 37 patients with head and neck malignancies, seven of whom had received prior treatment (18) . Nodal pO 2 measurement was acquired in one patient with nasopharyngeal SCC that was found to be very hypoxic: median pO 2 1.8 mmHg, HF 2.5 81%, HF 5.0 94% and HF 10.0 96%. Several other studies included a small number of NPC patients but did not provide individual patient data regarding the pO 2 measurements (20, 23) . Of interest, one of these studies evaluated the relationship between computed tomography (CT) derived tumour volume and hypoxic tumour volume as defined using pO 2 measurements (20) . The latter assessment was performed mainly on nodal masses. Two out of 125 patients had nasopharyngeal SCC. The study found that CT tumour volumes positively correlated with hypoxic volumes (HVs).
There are more published studies that evaluated pathological hypoxic markers in NPC ( Table 1 ) (36) (37) (38) (39) (40) (41) (42) (43) . Most studies evaluated HIF-1α expression which was found in 32-83% of patients ( Table 1 ). One study found that 57% of nasopharyngeal tumours expressed CA-IX (37) and VEGF expression was found in 41-80% (36, 37, 41, 42) . However, it should be noted that VEGF is not strictly a hypoxic marker, but rather an angiogenic marker whose expression is upregulated by HIF-1 (46) . Patients with NPC were found to have higher levels of plasma OPN compared to normal controls (mean 185 vs. 76 ng/mL, P=0.001) but no correlation to oxygenation status was made (44) . In a separate study, plasma OPN did not differ between patients with NPC and normal controls (45) .
Hypoxia as a prognostic biomarker
To our knowledge, there is no published study which evaluated invasive pO 2 status as a prognostic marker in NPC. On the other hand, pathological hypoxic biomarkers have been studied more extensively in NPC ( Table 2 ) (36-40, 42,47) . The majority of these studies investigated HIF-1α. All but one study (36) included predominantly the undifferentiated subtype. On an individual study level, the association between HIF-1α and locoregional control, disease-free survival (DFS) and OS were rather poor with the 95% confidence intervals (CI) crossing the 1.00 cutoff. Furthermore, its prognostic significance was lost after adjusting for confounding factors in multivariate analyses. Nonetheless, the prognostic values of HIF-1α and HIF-2α in head and neck cancers were supported in a recent systematic review (48) . A subset analysis included five studies (n=445) which looked solely at HIF-1α expression in NPC. Overexpression of HIF-1α was associated with inferior OS in all patients and also in the NPC subgroup (HR 2.07, 95% CI, 1.23-3.49). Fewer studies evaluated the prognostic role of CA-IX, VEGF and/or OPN but similar to HIF-1α, their prognostic significance was not conclusive in these retrospective studies ( Table 2) . Perhaps predictably, a combination of hypoxic, or hypoxic and angiogenic factors appeared to provide a more robust prognostic stratification (37, 42) .
Hypoxia imaging in NPC
Intuitively, a proportion of nasopharyngeal tumours will be hypoxic based on the extrapolation of current evidence in the HNSCC population. The degree of intratumoral hypoxia is likely to be greater with increasing tumour bulk. Besides being a potential prognostic biomarker, it would also be clinically beneficial if we could assess changes in intratumoral oxygenation during and after nonsurgical therapy, allowing us to intensify treatment, where appropriate. Both of the commonly used methods in hypoxia assessment, namely invasive pO 2 sampling and immunohistochemistry are associated with limitations. An ideal hypoxic biomarker should be hypoxia-specific with selective cellular uptake at a clinically relevant pO 2 level, reproducible, non-toxic and cost effective. While it is unlikely that any biomarker will fulfil all of these requirements, hypoxia imaging has gained considerable attention over recent years as it has the potential to fulfil most of these requirements. One of the major advantages of hypoxia imaging is its ability to acquire multiple high resolution 3-dimensional data over the regions of interest at different time points. We will review the available hypoxia imaging modalities which have been applied in NPC and novel imaging techniques that have the potential to be used in this disease. We will also discuss some relevant HNSCC studies when data on NPC is unavailable.
Positron emission tomography (PET)

Nitroimidazoles
There are several derivatives of nitroimidazole PET tracers in the clinical and research setting. In general, nitroimidazole enters the cell by passive diffusion and is reduced by nitroreductase enzymes to form RNO 2 radicals.
In the presence of oxygen, these radicals are rapidly reoxidised and the parent compound diffuses out of the cell. In hypoxic cells, the radical is further reduced and then binds to intracellular macromolecules, irreversibly trapping it within the cell (49 (77, 78) . To our knowledge, there is only one similar study in NPC which was published as an abstract (79) . This study included 40 patients who had The study also evaluated the association between the uptake of the tracers and CA-IX staining in nine patients. Both tracers showed good association with CA-IX expression.
Cu-ATSM
Cu-ATSM is a lipophilic Cu(II) complex that rapidly passes through the cell membrane. Its exact retention mechanism within hypoxic cells is still unclear (102, 103) . All hypotheses involve the reduction of Cu(II) to Cu(I) with various intracellular reducing agents being proposed such as mitochondrial nicotinamide adenine dinucleotide (NADH) (102) and cytoplasmic reductants such as NADPH (103) . It is thought that Cu-ATSM is reduced in both normoxic and hypoxic cells to the less lipophilic and unstable Cu(I)-ATSM complex. This process is reversible in the presence of oxygen, allowing the reoxidised Cu-ATSM to diffuse out of the cell. However, this is irreversible in the hypoxic environment, thus trapping the Cu(I) ions within hypoxic cells (104) (105) (106) . A number of copper isotopes with varying physical half-lives can be used to label this compound:
Cu (T 1/2 =3.3 hours), 62 Cu (T 1/2 =9.7 minutes) and 64 Cu (T 1/2 =12.7 hours) (49).
Due to very short half-life of 62 Cu, it has to be produced on-site in a 62 Zn/ 62 Cu generator (107) . The choice of isotopes will depend on studied hypothesis and availability of isotopes. The specificity of Cu-ATSM as a true hypoxia biomarker is still being debated. Table 4 shows the studies which have evaluated the evidence in this aspect (56, 61, 62, (108) (109) (110) . The hypoxia selectivity of Cu-ATSM has been suggested to be cell line (108, 111) and time dependent (56, 62) . This is supported by the finding that fatty acid synthase expression, a marker of tumour aggressiveness in prostate cancer, inhibited [
64 Cu]ATSM retention in several prostate carcinoma cell lines (112) . The conflicting evidence for its hypoxia selectivity may be partly attributed to all these reasons, leading to opinions that Cu-ATSM retention may not be entirely hypoxia specific but dictated by the intracellular redox potential (62, 113) . Despite this, Cu-ATSM uptake has been shown to be a significant prognostic factor in NSCLC, cervical and rectal cancers which could be independent of its status as a true hypoxic biomarker (114) (115) (116) . The role of Cu-ATSM PET in head and neck cancers has been studied but no published study has evaluated its Cu]ATSM SUV mean during treatment, these changes were less consistent in an individual patient basis which was similar to the preclinical findings of the heterogeneous Cu-ATSM uptake between different cell lines and xenografts.
Overall, there is very little evidence on the use of Cu-ATSM in NPC but the limited data in the head and neck cancer cohort suggests that there is potential for its use as a prognostic biomarker. Its use in radiotherapy planning is feasible but we are faced with the same difficulty as with the nitroimidazoles with regards to temporal variation in intratumoral oxygenation. In addition, the uncertainty of Cu-ATSM as a true hypoxia biomarker should ideally be resolved before it is used to direct hypoxia-targeting therapy.
Single photon emission computed tomography (SPECT)
SPECT hypoxia imaging is feasible although research into its use in the aspect has received less attention than PET in recent years. SPECT radiotracers typically have longer halflives compared to PET tracers, permitting delayed imaging to be performed. The spatial resolution and detection sensitivity of SPECT are lower than PET but a SPECT scanner is cheaper compared to PET which could be an important factor in terms of cost-effectiveness in certain healthcare systems (122) . Quantification of SPECT tracer uptake is also less developed compared to PET.
Iodoazomycin arabinoside (IAZA)
IAZA is a misonidazole analogue which has been proposed as an hypoxia imaging biomarker and can be coupled to iodine-123 ( to be used as a first-line imaging tool in detecting de novo or recurrent tumours.
Future directions
Molecular hypoxia imaging assessment in NPC is limited but we can probably extrapolate some data from the HNSCC population. There is perhaps less doubt about the significance of hypoxia as a negative prognostic and predictive factor in NPC than the actual prevalence of clinically and radiobiologically relevant hypoxia in this disease. Hence, more research should be done to ascertain the prevalence of hypoxia in NPC. A true hypoxia imaging biomarker which is not affected by tumour perfusion and blood flow, amongst other criteria as discussed before, will be the ideal clinical tool to use but such a biomarker is unlikely to exist. The future of hypoxia assessment is likely to involve multimodality functional imaging. Simultaneous assessment of hypoxia and perfusion/blood flow will be desirable, allowing oncologists to target the predominant process contributing to hypoxia. The combined use of different functional imaging modalities such as PET, magnetic resonance imaging (MRI) and CT should be considered. CT and MRI have advanced beyond conventional anatomical imaging. Functional MRI such as blood oxygen dependent (BOLD), dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI can provide additional evaluation of tumour oxygenation, perfusion/ blood flow and cellular density, respectively. BOLD MRI is based on the intrinsic differential magnetic properties of oxyhaemoglobin and deoxyhaemoglobin. The paramagnetic deoxyhaemoglobin shortens the T2* of blood and increases the MR transverse relaxation rate (R2* = 1/T2*) measured using gradient echo (GRE) sequences (131) . DCE-MRI evaluates the tumour enhancement characteristics before and after a fast bolus of intravenous low-molecular weight gadolinium contrast agent injection using T1-weighted spoiled GRE sequence (132) . The use of DCE-MRI has been recently been evaluated in NPC with encouraging results (133) (134) (135) . DW MRI measures the rate of water Brownian motion within tissues using a pair of field gradients with varying amplitudes and gradient durations which are both summarised as b-values, that defocus and refocus signals of water molecules (136) . Quantitative assessment is possible by acquiring images using at least two b-values to generate apparent diffusion coefficient (ADC) which is an average of water motion in three directions. Hypercellular tumours exhibit restricted diffusion and corresponding low ADC. Although often thought as measurement of tissue diffusivity, the DW signal attenuation is affected by both molecular diffusion and microcirculation of blood in the capillary network (137, 138) . Intravoxel incoherent motion (IVIM)-based analysis permits estimation of tumour perfusion and diffusivity by performing DW MRI using multiple b-values (usually more than 10). The measured signal attenuation acquired using low b-values is affected predominantly by microcapillary perfusion whereas signal attenuation at higher b-values is less sensitive to perfusion. IVIM-based analysis has been investigated in NPC to differentiate malignant tumours from radiation fibrosis (139) and benign tumours (140) , to predict locoregional tumour staging (141) and response to neoadjuvant chemotherapy (142) . Although initial results are promising, there are significant challenges to overcome before we can introduce this technique into clinical practice. Measurements of signal attenuation at low b-values are susceptible to signal-to-noise variations and have poor reproducibility. In addition, the optimal mathematical model to quantify perfusion and diffusion characteristics is still unclear (138) . Similar to DCE-MRI, perfusion CT assesses the temporal changes in tumour attenuation after intravenous iodinated contrast administration, allowing estimation of intratumoral blood flow, blood volume and vessel permeability (143, 144) . Although sequential PET and functional MRI/CT can be performed on different occasions, near simultaneous acquisitions of PET and MRI/ CT will be advantageous in terms of patient convenience and minimising the effect of temporal heterogeneity between scans. The introduction of PET/MRI has the potential to improve diagnostic and radiotherapy planning ability although there is still much uncertainty regarding the use of MR attenuation correction and research is still on going in this area. Nonetheless, this is an exciting prospect in hypoxia imaging particularly in NPC where the superior soft tissue definition on MRI will be clinically valuable.
Contrast-enhanced ultrasonography using microbubbles of injectable gas in a shell made up of phospholipids, proteins or polymer that remain intravascularly can be used to assess tumour perfusion (145) . These microbubbles of 1-4 μm in diameter are safe for patient use. The feasibility of this method to assess perfusion in liver and nodal metastases as well as renal cell carcinoma has been shown in a few studies (146) (147) (148) . Although not a direct assessment of hypoxia, contrast-enhanced ultrasonography could give additional perfusion/flow information which is related to the oxygenation status within the tumours. However, the availability of the microbubbles and the technical experience required have to be considered prior to its implementation.
Conclusions
Pathological evidence and to a lesser extent, invasive pO 2 assessment suggest that intratumoral hypoxia exists in a proportion of nasopharyngeal tumours, particularly in bulky primary and/or nodal disease. [
18 F]FMISO is the most widely studied imaging hypoxia biomarker, but its clinical use has been limited by its suboptimal pharmacokinetic properties. Newer generation nitroimidazoles and Cu-ATSM are viable alternatives although none of these tracers are without their limitations. Multimodality functional imaging with its potential to provide simultaneous information regarding perfusion, vessel permeability, tumour architecture and cellularity could herald a new paradigm in functional assessment of NPC.
